This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

5 Hated Stocks Set to Soar on Earnings

Regeneron Pharmaceuticals

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

A potential earnings short-squeeze play in the biotechnology and drugs complex is Regeneron Pharmaceuticals (REGN), which is set to release its numbers on Wednesday before the market open. This is an integrated biopharmaceutical firm, which discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Wall Street analysts, on average, expect Regeneron Pharmaceuticals to report revenue of $255.98 million on earnings of 25 cents per share.

If you're looking for a strong uptrending heavily-shorted biotech player ahead of its earnings report, then make sure to check out shares of Regeneron Pharmaceuticals. This stock has been on fire so far in 2012, with shares up over 121% so far. The current short interest as a percentage of the float for Regeneron Pharmaceuticals is notable at 6.3%. That means that out of the 88.13 million shares in the tradable float, 4.63 million shares are sold short by the bears.

>>5 Biotech Stocks Under $10 Set to Soar

From a technical perspective, REGN is currently trading above both its 50-day and 200-day moving averages, which is bullish. This stock recently found some big buying interest at around $107.31 to $111.50 a share. Since those buyers stepped in during the last month, shares of REGN have started to trend higher toward its current price of $122.50 a share and it's also moved within range of triggering a near-term breakout trade.

If you're in the bull camp on REGN, then I would wait until after its report and look for long-biased trades if this stock manages to take out some near-term overhead resistance at $124.85 a share (or its daily high from Tuesday if it's higher) with heavy volume. Look for volume on that move that registers near or above its three-month average action of 963,006 shares. If we get that move, then REGN will have a great chance of re-testing and possibly taking out its next major overhead resistance levels at $135 to $137.82 a share post-earnings.

I would simply avoid REGN or look for short-biased trades if after earnings this stock fails to trigger that breakout, and then moves back below Monday's low of $118.01 a share with heavy volume. If we get that move, then REGN will be trending back below its 50-day moving average of $122.51 a share, and this stock will likely head back towards those near-term support levels at $111.50 to $107.31 a share. If REGN takes out $107.31 a share with volume post-earnings, then this stock could easily fall all the way back towards its 200-day moving average of $95.68 a share if the bears slam this stock post-earnings.

Regeneron shows up on a recent list of 10 Stocks of Top-Performing Mutual Funds in 2012.

3 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,086.73 +15.51 0.09%
S&P 500 1,980.56 +2.76 0.14%
NASDAQ 4,513.8140 +7.9620 0.18%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs